e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Recent advances in our understanding of the treatment of asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
R. Louis, G. Joos, A. Michiels, G. Vandenhoven, I. De Schepper, V. Duquenne, M. Noppen (Liege, Ghent, Brussels, Belgium)
Source:
Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Session:
Recent advances in our understanding of the treatment of asthma
Session type:
Thematic Poster Session
Number:
3617
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Louis, G. Joos, A. Michiels, G. Vandenhoven, I. De Schepper, V. Duquenne, M. Noppen (Liege, Ghent, Brussels, Belgium). Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma. Eur Respir J 2007; 30: Suppl. 51, 3617
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Budesonide/formoterol maintenance and reliever therapy compared with conventional best standard treatment
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008
Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
Source: Eur Respir J 2006; 28: Suppl. 50, 613s
Year: 2006
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma
Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017
Year: 2018
Budesonide/formoterol maintenance and reliever therapy – effective treatment at a lower cost
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations
versus
a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006
Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Overall asthma control with budesonide/formoterol maintenance and relief vs conventional best practice
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008
Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers?
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010
Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001
Budesonide/formoterol for maintenance and reliever therapy in real-life in Thailand
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003
Variation of regular maintenance therapy with budesonide/formoterol of children with asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept